Publicaciones en colaboración con investigadores/as de Institució Catalana de Recerca i Estudis Avançats (7)

2022

  1. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

2021

  1. Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108

2017

  1. Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 23, Núm. 22, pp. 7006-7019

  2. Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity

    Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651

2016

  1. Targeting the EGF/HER ligand-receptor system in cancer

    Current Pharmaceutical Design, Vol. 22, Núm. 39, pp. 5887-5898

2014

  1. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy

    Journal of the National Cancer Institute, Vol. 106, Núm. 11

2013

  1. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers

    Oncogene, Vol. 32, Núm. 11, pp. 1452-1459